Q-omics provides the consensus-scored ARHGAP27P1-BPTFP1-KPNA2P3 profile across patient tissues and cancer cell-line models. ARHGAP27P1-BPTFP1-KPNA2P3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ARHGAP27P1-BPTFP1-KPNA2P3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ARHGAP27P1-BPTFP1-KPNA2P3 RNA expression shows 18,121 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where ARHGAP27P1-BPTFP1-KPNA2P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGAP27P1-BPTFP1-KPNA2P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGAP27P1-BPTFP1-KPNA2P3 survival associations across molecular data types. ARHGAP27P1-BPTFP1-KPNA2P3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGAP27P1-BPTFP1-KPNA2P3 RNA expression–survival associations across cancer types. High ARHGAP27P1-BPTFP1-KPNA2P3 expression shows unfavorable associations in KIRC, COAD and PRAD, but favorable associations in BLCA, SKCM and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ARHGAP27P1-BPTFP1-KPNA2P3 RNA expression.
This table summarizes ARHGAP27P1-BPTFP1-KPNA2P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGAP27P1-BPTFP1-KPNA2P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGAP27P1-BPTFP1-KPNA2P3 shows lower tumor expression in KICH and higher tumor expression in KIRC, THCA, LIHC, BLCA and COAD. The KIRC box plot shows higher ARHGAP27P1-BPTFP1-KPNA2P3 RNA expression in tumor versus normal tissue (log2 FC = +0.661, t-test p < 0.001).
This table shows molecular features associated with ARHGAP27P1-BPTFP1-KPNA2P3 in patient tissues and cancer cell lines. In patient samples, ARHGAP27P1-BPTFP1-KPNA2P3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGAP27P1-BPTFP1-KPNA2P3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
